<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253084</url>
  </required_header>
  <id_info>
    <org_study_id>IPX054-B04-07</org_study_id>
    <nct_id>NCT00253084</nct_id>
  </id_info>
  <brief_title>Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMPAX Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release
      carbidopa-levodopa in subjects with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPX054 contains two different drugs called levodopa and carbidopa in one tablet.

        -  levodopa turns into a material called 'dopamine' in your brain. The dopamine helps to
           improve the symptoms of your Parkinson's disease.

        -  carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase
           inhibitors'. It helps levodopa work more effectively by slowing the speed at which
           levodopa is broken down in your body.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;ON&quot; time without disabling dyskinesias</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS analysis</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to &quot;ON&quot;</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to &quot;wearing OFF&quot;</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>IPX054 - CD-LD IR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD-LD IR - IPX054</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 200 mg</intervention_name>
    <description>IPX054 containing 50 mg carbidopa and 200 mg levodopa</description>
    <arm_group_label>IPX054 - CD-LD IR</arm_group_label>
    <arm_group_label>CD-LD IR - IPX054</arm_group_label>
    <other_name>CD-LD ER 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-LD IR</intervention_name>
    <description>CD-LD IR containing 25 mg carbidopa and 100 mg levodopa</description>
    <arm_group_label>IPX054 - CD-LD IR</arm_group_label>
    <arm_group_label>CD-LD IR - IPX054</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 Placebo</intervention_name>
    <description>Placebo to match IPX054 200 mg</description>
    <arm_group_label>IPX054 - CD-LD IR</arm_group_label>
    <arm_group_label>CD-LD IR - IPX054</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-LD IR Placebo</intervention_name>
    <description>Placebo to match CD-LD IR</description>
    <arm_group_label>IPX054 - CD-LD IR</arm_group_label>
    <arm_group_label>CD-LD IR - IPX054</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with idiopathic Parkinson's disease based on CAPIT (Core Assessment Program
             for Intracerebral Transplantations) criteria.

          -  Currently being treated with immediate-release carbidopa-levodopa with a stable dosing
             regimen over the past 4 weeks.

        Exclusion Criteria:

          -  Diagnosed with atypical parkinsonism.

          -  Allergic or non-responsive to previous carbidopa-levodopa therapy.

          -  Active or history of narrow-angle or wide-angle glaucoma.

          -  History of seizure or epilepsy, or is currently taking an anti-convulsant for
             treatment of seizure.

          -  Requires concomitant therapy with tricyclic antidepressants, MAO-B inhibitors, COMT
             inhibitors or anticholinergics.

          -  Treatment with any neuroleptic agent, including atypical neuroleptics, within the
             previous 6 months.

          -  Treatment with any dopaminergic blocking agent within the previous 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Impax</last_name>
    <role>Study Director</role>
    <affiliation>Impax Pharmaceuticals, a division of Impax Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

